Skip to main content
. 2016 Sep 30;38(5):1433–1442. doi: 10.3892/ijmm.2016.2763

Figure 5.

Figure 5

Co-administration of rolipram (ROL) and SP600125 attenuates thermal hyperalgesia and chemokine (C-C motif) ligand 2 (CCL2) expression in rats with bone cancer pain (BCP). The intrathecal administration of SP600125 significantly attenuated thermal hyperalgesia compared with the vehicle control. The co-administration of ROL and SP600125 did not exert more potent effects on (A) paw withdrawal latency and (B) CCL2 expression compared to the administration of ROL alone. Tissues were collected 20 days following inoculation. **p<0.01; n.s., no significance; Veh, vehicle; Sham, sham-operated; SP, SP600125. Four rats were included in each group.